Clinical and Observational Trials
-
Principal Investigator:
Uma M. Reddy, MD, MPH
This research study is being done to understand how CPAP for sleep apnea may affect hypertensive disorders of pregnancy and other complications of pregnancy such as gestational diabetes. The purpose of the home sleep test is to find women with sleep apnea. Sleep apnea is when you have one or more pauses in breathing or shallow breaths while you sleep. Studies have shown that women with sleep apnea have an increased risk of high blood pressure and diabetes during pregnancy. If the test shows that you have sleep apnea in the mild to moderate range you will be eligible for a research study to...
-
Principal Investigator:
Jason D. Wright, MD
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for longer and/or improve your quality of life after surgery. Both the minimally invasive surgery and laparotomy procedures in this study are performed using FDA-approved and commercially available methods. It is considered investigational to...
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking into possible viral causes of stillbirth or late-term miscarriages in patients. We are looking for people who have recently had a late-term pregnancy loss (within the past week). Participation in this research involves a one-time blood draw. Participants will receive $50.
-
Principal Investigator:
Noelia M. Zork, MD
Women will be enrolled at or prior to prenatal visit at 34-40 weeks gestation with follow-up visits within 48 hours of delivery, and 6 and 12 months postpartum among the mother and infant. Maternal and infant measurements will be conducted at each visit. The purpose of the study is to estimate cardiovascular disease risk in healthy and medically complicated pregnant women and their infants 840 mother-infant dyads.
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking at the changes that happen in the placenta when people become pregnant. Participation in this study involves a blood draw at three time points. Participants will be paid $50 at each time point. Participants who complete all three time points will receive bonus compensation.
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking at the changes that happen in the placenta when people become pregnant. Participation in this study involves a blood draw at three time points. Participants will be paid $50 at each time point. Participants who complete all three time points will receive bonus compensation.
-
Principal Investigator:
Uma M. Reddy, MD, MPH
This study will enroll participants who did or did not receive a SARS-CoV-2 vaccine during their pregnancy and have a child who is now 18-30 months of age. In order to assess the long-term outcomes of the offspring of those who received SARS-CoV-2 vaccine in pregnancy, a cohort study examining child developmental outcomes is needed. There are a number of known tests of developmental milestones that are easy to administer and can be administered remotely.
-
Principal Investigator:
June Y. Hou, MD
In this research study, an investigational medication named ACR-368 (also known as prexasertib) is being tested for the treatment of ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination therapy). ACR-368 has not been approved for use as a treatment for any condition, by government agencies in any country. ACR-368 is a type of medication called a checkpoint kinase inhibitor which may...
-
Principal Investigator:
June Y. Hou, MD
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
-
Principal Investigator:
June Y. Hou, MD
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of cancer cells. The study drugs, TransCon TLR7/8 Agonist and TransCon IL-2 /, have not been approved to be used by the Food and Drug Administration FDA for this study population. TransCon IL-2 / and TransCon TLR7/8 Agonist whereas designed...
